UA93387C2 - Производные пиримидина и их применение b качестве открывателей калиевых каналов kcnq - Google Patents
Производные пиримидина и их применение b качестве открывателей калиевых каналов kcnqInfo
- Publication number
- UA93387C2 UA93387C2 UAA200803570A UAA200803570A UA93387C2 UA 93387 C2 UA93387 C2 UA 93387C2 UA A200803570 A UAA200803570 A UA A200803570A UA A200803570 A UAA200803570 A UA A200803570A UA 93387 C2 UA93387 C2 UA 93387C2
- Authority
- UA
- Ukraine
- Prior art keywords
- pyrimidine derivatives
- potassium channels
- kcnq potassium
- openers
- channels openers
- Prior art date
Links
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title abstract 2
- 150000003230 pyrimidines Chemical class 0.000 title abstract 2
- 102000012359 KCNQ Potassium Channels Human genes 0.000 title 1
- 108010022282 KCNQ Potassium Channels Proteins 0.000 title 1
- 102000004257 Potassium Channel Human genes 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 108020001213 potassium channel Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200501262 | 2005-09-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA93387C2 true UA93387C2 (ru) | 2011-02-10 |
Family
ID=37199174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200803570A UA93387C2 (ru) | 2005-09-09 | 2006-09-07 | Производные пиримидина и их применение b качестве открывателей калиевых каналов kcnq |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1937653A1 (es) |
| JP (1) | JP2009507052A (es) |
| KR (1) | KR20080043314A (es) |
| CN (1) | CN101258133A (es) |
| AR (1) | AR055420A1 (es) |
| AU (1) | AU2006322461A1 (es) |
| BR (1) | BRPI0615631A2 (es) |
| CA (1) | CA2621854A1 (es) |
| EA (1) | EA200800780A1 (es) |
| IL (1) | IL189545A0 (es) |
| MX (1) | MX2008002294A (es) |
| NO (1) | NO20081713L (es) |
| UA (1) | UA93387C2 (es) |
| WO (1) | WO2007065449A1 (es) |
| ZA (1) | ZA200802174B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA97847C2 (ru) * | 2007-08-01 | 2012-03-26 | Х. Луннбек А/С | Применение соединений, которые открывают калиевые каналы kcnq, для лечения дефицита внимания/гиперактивности (adhd) или агрессии |
| US7786146B2 (en) * | 2007-08-13 | 2010-08-31 | Valeant Pharmaceuticals International | Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators |
| WO2010097379A1 (en) * | 2009-02-24 | 2010-09-02 | Neurosearch A/S | Substituted pyrimidin derivatives and their medical use |
| JP5763758B2 (ja) * | 2010-07-08 | 2015-08-12 | ファイザー・インク | Kv7カリウムチャネル開口薬としてのピペリジニルピリミジンアミド |
| WO2012052167A1 (en) * | 2010-10-20 | 2012-04-26 | Grünenthal GmbH | Substituted 6-amino-nicotinamides as kcnq2/3 modulators |
| CN103508960B (zh) * | 2012-06-29 | 2017-12-12 | 江苏先声药业有限公司 | 苯并杂环衍生物 |
| CN103508943B (zh) * | 2012-06-29 | 2017-06-09 | 江苏先声药业有限公司 | 作为钾通道调节剂的化合物 |
| TWI664166B (zh) * | 2014-10-24 | 2019-07-01 | 日商小野藥品工業股份有限公司 | Kcnq2至5通道活化劑 |
| ES3034153T3 (en) * | 2019-08-02 | 2025-08-13 | H Lundbeck As | Alcohol derivatives as kv7 potassium channel openers for use in epilepsy or seizures |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2438231A1 (en) * | 2001-02-20 | 2002-08-29 | Gene G. Kinney | 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators |
| WO2003068769A1 (en) * | 2002-02-12 | 2003-08-21 | Pfizer Inc. | Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh) |
| US20080261918A1 (en) * | 2004-12-17 | 2008-10-23 | Graham Andrew Showell | Silicon Compounds and Their Use |
-
2006
- 2006-09-07 KR KR1020087004306A patent/KR20080043314A/ko not_active Withdrawn
- 2006-09-07 EP EP06846967A patent/EP1937653A1/en not_active Withdrawn
- 2006-09-07 JP JP2008529473A patent/JP2009507052A/ja not_active Withdrawn
- 2006-09-07 WO PCT/DK2006/050039 patent/WO2007065449A1/en not_active Ceased
- 2006-09-07 UA UAA200803570A patent/UA93387C2/ru unknown
- 2006-09-07 CN CNA2006800327125A patent/CN101258133A/zh active Pending
- 2006-09-07 CA CA002621854A patent/CA2621854A1/en not_active Abandoned
- 2006-09-07 ZA ZA200802174A patent/ZA200802174B/xx unknown
- 2006-09-07 BR BRPI0615631-2A patent/BRPI0615631A2/pt not_active IP Right Cessation
- 2006-09-07 EA EA200800780A patent/EA200800780A1/ru unknown
- 2006-09-07 MX MX2008002294A patent/MX2008002294A/es active IP Right Grant
- 2006-09-07 AU AU2006322461A patent/AU2006322461A1/en not_active Abandoned
- 2006-09-08 AR ARP060103924A patent/AR055420A1/es not_active Application Discontinuation
-
2008
- 2008-02-14 IL IL189545A patent/IL189545A0/en unknown
- 2008-04-09 NO NO20081713A patent/NO20081713L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006322461A1 (en) | 2007-06-14 |
| NO20081713L (no) | 2008-06-04 |
| CA2621854A1 (en) | 2007-06-14 |
| EP1937653A1 (en) | 2008-07-02 |
| WO2007065449A1 (en) | 2007-06-14 |
| AR055420A1 (es) | 2007-08-22 |
| CN101258133A (zh) | 2008-09-03 |
| KR20080043314A (ko) | 2008-05-16 |
| EA200800780A1 (ru) | 2008-06-30 |
| JP2009507052A (ja) | 2009-02-19 |
| IL189545A0 (en) | 2008-06-05 |
| ZA200802174B (en) | 2009-10-28 |
| BRPI0615631A2 (pt) | 2011-05-24 |
| MX2008002294A (es) | 2008-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200800968A (en) | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | |
| WO2007027238A3 (en) | Jak kinase inhibitors and their uses | |
| SG164368A1 (en) | Treatment of cancer | |
| GEP20094785B (en) | Pyrrolopyrazoles, potent kinase inhibitors | |
| UA85559C2 (en) | Aminobenzophenone compounds | |
| UA102251C2 (ru) | Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера | |
| EA200970575A1 (ru) | Соединения на основе 4-фенил-6-(2,2,2-трифтор-1-фенилэтокси)пиримидина и способы их применения | |
| WO2009077471A3 (de) | Azolylmethyloxirane, ihre verwendung sowie sie enthaltende mittel | |
| EA200700633A1 (ru) | Производные замещённого анилина | |
| IL190730A0 (en) | Potassium channel inhibitors | |
| MX2009013515A (es) | Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica. | |
| UA83875C2 (ru) | Производные хинолина для применения в качестве микобактериальных ингибиторов | |
| NO20081713L (no) | Pyrimidinderivater og deres anvendelse som KCNQ-kaliumkanalapnere | |
| WO2007097981A3 (en) | Alpha carbolines and uses thereof | |
| TW200624426A (en) | BACE inhibitors | |
| IL205696A0 (en) | Heterocyclic derivatives, compositions comprising the same and uses thereof | |
| WO2007067559A3 (en) | Antibacterial agents | |
| TW200630367A (en) | Substituted adenines and the uses thereof | |
| UA84954C2 (ru) | Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования | |
| TW200700064A (en) | Novel compounds | |
| MX2010009276A (es) | Pirrolopirimidincarboxamidas. | |
| UA90698C2 (en) | Triazole substituted aminobenzophenone compounds | |
| MX2009009490A (es) | Profarmacos novedosos. | |
| PL1937669T3 (pl) | Nowe pochodne benzopiranu jako „otwieracze" kanału potasowego | |
| MX2008001428A (es) | Compuestos de imidazolil-pirimidina para uso en el tratamiento de trastornos proliferativos. |